ENDPOINTS

Biopharma execs rethink Trump impact after FDA cuts

This week’s sweeping layoffs at the FDA have caused some biopharma leaders to change their tune on the Trump administration. After President Donald Trump’s victory in November, many biopharma CEOs ranged from cautious optimism to ...

Apr 2, 2025 - 20:48
 0
Biopharma execs rethink Trump impact after FDA cuts
This week’s sweeping layoffs at the FDA have caused some biopharma leaders to change their tune on the Trump administration. After President Donald Trump’s victory in November, many biopharma CEOs ranged from cautious optimism to ...
Read More

Tags:

Previous Article

Mysterious origin of iconic Sutton Hoo helmet possibly revealed in new research

Next Article

LOOKING GLASS: Exploring Titan's Icy Hydrocarbon Cycle

Related Posts

Jazz to buy Chimerix for $935M to get brain tumor drug five months ahead of PDUFA

Jazz to buy Chimerix for $935M to get brain tumor drug ...

Mar 5, 2025  0

Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D

Ascletis’ not-so-great weight loss data; Vivace’s $35M ...

Mar 12, 2025  0

Ophthalmology startup Character Biosciences gets $93M for genetics-based approach

Ophthalmology startup Character Biosciences gets $93M f...

Mar 25, 2025  0